Advanced in Ovarian Cancer

Dr. Ioannis A. Voutsadakis

Oncology
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
Advanced in Ovarian Cancer
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ioannis Voutsadakis is an Oncologist in Iowa City, Iowa. Dr. Voutsadakis is rated as an Advanced provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Breast Cancer, Colorectal Cancer, Ovarian Cancer, and Stomach Cancer.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 2 clinical trials in the study of Ovarian Cancer.

Specialties
Oncology
Licenses
Internal Medicine in IA
Hospital Affiliations
University Of Iowa Hospital & Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

STATE UNIVERSITY OF IOWA
200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer
A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
View 8 Less Clinical Trials

180 Total Publications

The Landscape of Genomic Alterations in Receptor Tyrosine Kinase Pathways in Biliary Cancers: Implications for Targeted Therapies.
The Landscape of Genomic Alterations in Receptor Tyrosine Kinase Pathways in Biliary Cancers: Implications for Targeted Therapies.
Journal: Journal of gastrointestinal cancer
Published: October 13, 2025
Similar Doctors
Elite in Ovarian Cancer
Dr. David P. Bender
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Ovarian Cancer
Dr. David P. Bender
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Bender is a Gynecologic Oncologist and an Oncologist in Iowa City, Iowa. Dr. Bender is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Bladder Reconstruction. Dr. Bender is currently accepting new patients.

Elite in Ovarian Cancer
Dr. Michael J. Goodheart
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Ovarian Cancer
Dr. Michael J. Goodheart
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Michael Goodheart is a Gynecologic Oncologist and an Oncologist in Iowa City, Iowa. Dr. Goodheart is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Hysterectomy, and Salpingo-Oophorectomy. Dr. Goodheart is currently accepting new patients.

Distinguished in Ovarian Cancer
Dr. Jesus Gonzalez-Bosquet
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Cancer
Dr. Jesus Gonzalez-Bosquet
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jesus Gonzalez-Bosquet is a Gynecologic Oncologist and an Oncologist in Iowa City, Iowa. Dr. Gonzalez-Bosquet is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Gastrostomy. Dr. Gonzalez-Bosquet is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Voutsadakis's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile